《胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识（2018版）》解读之直接口服抗凝药应用前瞻篇

Perioperative Venous Thromboembolism(VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus-Interpretation of Application Prospect of Direct Oral Anticoagulant

胸部恶性肿瘤患者围术期静脉血栓栓塞症(venous thromboembolism,VTE)是一种需要引起重视的胸外科围术期并发症,中国胸外科静脉血栓栓塞研究协作组针对胸部恶性肿瘤患者围术期VTE的预防,发布了国际首部《胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识》(2018版)。本文将对直接口服抗凝药在胸部恶性肿瘤患者围术期的应用进行解读,以助于更好地理解共识相关内容。

Venous thromboembolism(VTE) is a preventable perioperative complication of malignant tumor in thoracic surgery.At present,low molecular weight heparin anticoagulants are the first choices for perioperative drug prevention of malignant tumors,and direct oral anticoagulants are not recommended for perioperative use of malignant tumors in thoracic surgery,but their application in other related fields is relatively mature.This article will introduce direct oral anticoagulants and analyze the prospect of their perioperative application in patients with thoracic malignant tumors.It is helpful to better understand the relevant contents of "perioperative VTE prophylaxis in thoracic cancer patients:Chinese experts consensus(2018 edition)".